Octreotide may act as a radioprotective agent in acromegaly

J Clin Endocrinol Metab. 2000 Mar;85(3):1287-9. doi: 10.1210/jcem.85.3.6464.


Clinical experience shows that an increasing number of patients undergoing radiation treatment for recurring acromegaly or acromegaly persisting after surgery are treated with octreotide. We, therefore, performed a follow-up study of patients undergoing stereotactic radiosurgery (Gamma Knife) to determine whether this medication has an influence on the ultimate result of radiation therapy in either a positive or negative sense. It has been suggested that the combination of radiation with antisecretory drugs may increase the effectiveness of radiation. A follow-up study of 31 patients suffering from recurrent acromegaly and acromegaly persisting after surgery, and who had been treated with stereotactic radiosurgery, showed that patients treated with octreotide at the time of radiation application simultaneously reached a normal level of growth hormone and insulin-like growth factor-I only after a significantly longer interval than patients who did not receive the drug. The two groups of patients did not demonstrate significant differences in the main clinical findings (age, sex, target volume, radiation dose, baseline growth hormone, and baseline insulin-like growth factor-I).

Publication types

  • Clinical Trial

MeSH terms

  • Acromegaly / etiology
  • Acromegaly / radiotherapy*
  • Adenoma / complications
  • Adenoma / therapy
  • Adult
  • Aged
  • Female
  • Human Growth Hormone / blood
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Middle Aged
  • Octreotide / pharmacology*
  • Pituitary Neoplasms / complications
  • Pituitary Neoplasms / therapy
  • Radiation-Protective Agents / pharmacology*
  • Radiosurgery
  • Retrospective Studies


  • Radiation-Protective Agents
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Octreotide